Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Authors
Thatcher, NickHirsch, F
Luft, A
Szczesna, A
Ciuleanu, T
Dediu, M
Ramlau, R
Galiulin, R
Bálint, B
Losonczy, G
Kazarnowicz, A
Park, K
Schumann, C
Reck, M
Depenbrock, H
Nanda, S
Kruljac-Letunic, A
Kurek, R
Paz-Ares, L
Socinski, M
Affiliation
The Christie Hospital, Manchester, UK.Issue Date
2015-07
Metadata
Show full item recordAbstract
Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer.Citation
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. 2015, 16 (7):763-74 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(15)00021-2PubMed ID
26045340Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00021-2